TRB Chemedica’s Vouvry site brings together GMP manufacturing, pharmaceutical-grade hyaluronic acid expertise, ganglioside extraction and integrated R&D. The site illustrates the specialised industrial competence base that strengthens Valais’ position in pharmaceutical manufacturing.
Founded in 1980, TRB Chemedica is a Swiss biopharmaceutical company active in ophthalmology, musculoskeletal health and neurology. The group is present in more than 70 countries and employs more than 900 people worldwide.
Its Swiss representation is based in Vouvry, Valais, where production and R&D operate in close proximity. The site is structured around two production units and a dedicated R&D department. It works under demanding quality frameworks, including GMP, ISO 13485 and GDP certifications listed by TRB Switzerland.
For Valais, the point is not only that a pharmaceutical company is present. It is that a specific industrial competence is anchored locally.
Gangliosides, hyaluronic acid and process control
The first production unit focuses on ganglioside extraction and purification. This is a narrow, high-precision field requiring control over complex biological material, purification steps, analytical discipline and scale-up know-how.
The second unit manufactures injectable products based on hyaluronic acid. TRB identifies pharmaceutical-grade sodium hyaluronate as one of its core areas of expertise, with applications across musculoskeletal health and ophthalmology.
These activities are not generic manufacturing. They require process stability, regulatory discipline, technical continuity and the ability to maintain quality across specialised product families.
That is where the competence story becomes strategic.
R&D embedded in manufacturing reality
TRB’s Vouvry site is not organised as a separated production asset. Its R&D unit works closely with the production division and contributes to methods and procedures used on site.
This proximity matters in a region positioning itself around life sciences industrialisation.
For companies operating in regulated environments, expertise is built through the continuous interaction between development, engineering, production, quality and industrial constraints. The value lies in the teams able to adapt processes, solve deviations, transfer know-how and keep manufacturing robust over time.
Vouvry shows this operational layer clearly.
Why this matters for Valais
Valais is strongest where life sciences innovation meets production reality.
The canton already brings together major industrial anchors, GMP infrastructure, applied research, technical suppliers, engineering capabilities and specialised training. This creates an environment where competencies are not abstract. They are used in production sites, quality systems, pilot projects, industrial services and scale-up contexts.
TRB Chemedica adds to this picture through a site where pharmaceutical production depends on deep technical expertise and continuity of know-how.
For startups, SMEs and international companies evaluating Switzerland, this is a relevant signal. Valais offers access not only to infrastructure, but to an ecosystem shaped by people who understand regulated manufacturing, process development, industrial transfer and operational execution.
Competence as an ecosystem asset
In life sciences, infrastructure matters. But infrastructure without expertise is static.
What makes a territory credible is the competence base around it: the scientists, process specialists, quality teams, engineers, technicians and industrial managers who turn technical complexity into controlled production.
TRB Chemedica’s Vouvry site is one of the examples that makes this visible in Valais.
It shows a region where life sciences capabilities are not only described. They are practiced.
